Similarly, another study showed increased YBX1 expression in 32 renal cell carcinoma (RCC) patients, and the genetic ablation of YBX1 in vitro was shown to inhibit the phosphorylation of NF-κB on S536. The gene discussed is NFKB1; the disease is renal cell carcinoma.